CA2330210A1 - Activite de proteasomes - Google Patents
Activite de proteasomes Download PDFInfo
- Publication number
- CA2330210A1 CA2330210A1 CA002330210A CA2330210A CA2330210A1 CA 2330210 A1 CA2330210 A1 CA 2330210A1 CA 002330210 A CA002330210 A CA 002330210A CA 2330210 A CA2330210 A CA 2330210A CA 2330210 A1 CA2330210 A1 CA 2330210A1
- Authority
- CA
- Canada
- Prior art keywords
- proteasomal
- assay
- protein
- tat
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000694 effects Effects 0.000 title claims abstract description 85
- 238000003556 assay Methods 0.000 claims abstract description 80
- 101710149951 Protein Tat Proteins 0.000 claims abstract description 74
- 150000001875 compounds Chemical class 0.000 claims abstract description 74
- 239000003112 inhibitor Substances 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 30
- 230000006378 damage Effects 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 9
- 230000001580 bacterial effect Effects 0.000 claims abstract description 8
- 108091006104 gene-regulatory proteins Proteins 0.000 claims abstract description 8
- 102000034356 gene-regulatory proteins Human genes 0.000 claims abstract description 8
- 208000036142 Viral infection Diseases 0.000 claims abstract description 7
- 230000029812 viral genome replication Effects 0.000 claims abstract description 7
- 230000009385 viral infection Effects 0.000 claims abstract description 7
- 230000009447 viral pathogenesis Effects 0.000 claims abstract description 6
- 230000008859 change Effects 0.000 claims abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 81
- 102000004169 proteins and genes Human genes 0.000 claims description 77
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 71
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 71
- 210000004027 cell Anatomy 0.000 claims description 41
- 101710163270 Nuclease Proteins 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 108091034117 Oligonucleotide Proteins 0.000 claims description 21
- 230000005764 inhibitory process Effects 0.000 claims description 21
- 108091005804 Peptidases Proteins 0.000 claims description 20
- 239000004365 Protease Substances 0.000 claims description 20
- 239000000758 substrate Substances 0.000 claims description 19
- 230000002797 proteolythic effect Effects 0.000 claims description 17
- 108010067390 Viral Proteins Proteins 0.000 claims description 16
- 208000030507 AIDS Diseases 0.000 claims description 15
- 230000001965 increasing effect Effects 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 15
- 238000003776 cleavage reaction Methods 0.000 claims description 14
- 230000007017 scission Effects 0.000 claims description 14
- 102000004127 Cytokines Human genes 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 13
- 102100031780 Endonuclease Human genes 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 108010042407 Endonucleases Proteins 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 10
- 230000014509 gene expression Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 108020000999 Viral RNA Proteins 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 230000004063 proteosomal degradation Effects 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 210000000805 cytoplasm Anatomy 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 4
- 239000000816 peptidomimetic Substances 0.000 claims description 4
- 229920002477 rna polymer Polymers 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 3
- 102000008072 Lymphokines Human genes 0.000 claims description 3
- 108010074338 Lymphokines Proteins 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000004020 luminiscence type Methods 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 210000000605 viral structure Anatomy 0.000 claims description 3
- 108020004513 Bacterial RNA Proteins 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 6
- 239000003443 antiviral agent Substances 0.000 claims 2
- 108700019146 Transgenes Proteins 0.000 claims 1
- 238000002835 absorbance Methods 0.000 claims 1
- 230000000254 damaging effect Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 abstract description 23
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 19
- FXYZDFSNBBOHTA-UHFFFAOYSA-N 2-[amino(morpholin-4-ium-4-ylidene)methyl]guanidine;chloride Chemical compound Cl.NC(N)=NC(=N)N1CCOCC1 FXYZDFSNBBOHTA-UHFFFAOYSA-N 0.000 abstract description 6
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 55
- 108700025184 hepatitis B virus X Proteins 0.000 description 22
- 230000006870 function Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- 238000006731 degradation reaction Methods 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 230000015556 catabolic process Effects 0.000 description 16
- 102000035195 Peptidases Human genes 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 11
- 229910001629 magnesium chloride Inorganic materials 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 102000006382 Ribonucleases Human genes 0.000 description 9
- 108010083644 Ribonucleases Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 108091054437 MHC class I family Proteins 0.000 description 6
- 102000044159 Ubiquitin Human genes 0.000 description 6
- 108090000848 Ubiquitin Proteins 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108020005176 AU Rich Elements Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 4
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- 238000010798 ubiquitination Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101000592466 Homo sapiens Proteasome subunit beta type-4 Proteins 0.000 description 3
- 102100033190 Proteasome subunit beta type-4 Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 3
- 102100037587 Ubiquitin carboxyl-terminal hydrolase BAP1 Human genes 0.000 description 3
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 3
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- AUUIARVPJHGTSA-UHFFFAOYSA-N 3-(aminomethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(CN)=CC2=C1 AUUIARVPJHGTSA-UHFFFAOYSA-N 0.000 description 2
- 108091027075 5S-rRNA precursor Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101710177291 Gag polyprotein Proteins 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 102000027450 oncoproteins Human genes 0.000 description 2
- 108091008819 oncoproteins Proteins 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UVFAEQZFLBGVRM-MSMWPWNWSA-N succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CCC(O)=O)CC(C)C)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C1=CC=C(O)C=C1 UVFAEQZFLBGVRM-MSMWPWNWSA-N 0.000 description 2
- 108700004027 tat Genes Proteins 0.000 description 2
- 101150098170 tat gene Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102100025566 Chymotrypsin-like protease CTRL-1 Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102100038591 Endothelial cell-selective adhesion molecule Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 1
- 101000882622 Homo sapiens Endothelial cell-selective adhesion molecule Proteins 0.000 description 1
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 1
- 101900141355 Human T-cell leukemia virus 1 Protein Tax-1 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 101150091206 Nfkbia gene Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 description 1
- 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 description 1
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 1
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000004670 cellular proteolysis Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000026938 proteasomal ubiquitin-dependent protein catabolic process Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 108010038751 tax Gene Products Proteins 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2337/00—N-linked chromogens for determinations of peptidases and proteinases
- C12Q2337/20—Coumarin derivatives
- C12Q2337/22—7-Amino-4-methylcoumarin, i.e. AMC, MCA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
- G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La présente invention concerne la modulation et/ou la régulation de l'activité de protéasomes. L'invention concerne des méthodes diagnostiques d'identification de composés inhibant une réplication virale et une pathogenèse, une méthode d'identification d'inhibiteurs de la fonction inhibitrice de nucléase de la protéine TAT du virus de l'immunodéficience humaine, des méthodes d'identification d'inhibiteurs de la fonction inhibitrice de protéase de la protéine TAT du virus de l'immunodéficience humaine, des méthodes d'identification de composés qui modifient les concentrations de protéines régulatrices en modulant la vitesse de destruction de protéasomes d'ARN messagers spécifiques, et des méthodes de génération d'une résistance aux lésions dues à une infection bactérienne ou virale. L'invention concerne des méthodes diagnostiques, des trousses d'application de ces méthodes diagnostiques, des composés identifiés par ces méthodes diagnostiques, ainsi que des séquences d'acides aminés codant ces composés et des compositions médicamenteuses dérivées de ces composés. Lorsque la loi le permet, l'invention concerne également des méthodes de traitement sur la base de la modulation/régulation de l'activité de protéasomes.
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9812758.2 | 1998-06-13 | ||
| GB9812757.4 | 1998-06-13 | ||
| GBGB9812756.6A GB9812756D0 (en) | 1998-06-13 | 1998-06-13 | Assay procedure for identifying inhibitors of the nuclease-inhibitory function of the human immunodeficiency virus tat protein |
| GBGB9812759.0A GB9812759D0 (en) | 1998-06-13 | 1998-06-13 | A procedure for generating resistance to bacterial or viral infection damage |
| GBGB9812758.2A GB9812758D0 (en) | 1998-06-13 | 1998-06-13 | Proteasomal destruction of mRNA |
| GB9812756.6 | 1998-06-13 | ||
| GBGB9812760.8A GB9812760D0 (en) | 1998-06-13 | 1998-06-13 | A method for identifying compounds which inhibit viral replication and pathogenesis |
| GB9812759.0 | 1998-06-13 | ||
| GBGB9812757.4A GB9812757D0 (en) | 1998-06-13 | 1998-06-13 | Assay procedure for identifying inhibitors of the protease-inhibitory function of the human immunodeficiency virus tat protein |
| GB9812760.8 | 1998-06-13 | ||
| PCT/GB1999/001840 WO1999066065A2 (fr) | 1998-06-13 | 1999-06-10 | Activite de proteasomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2330210A1 true CA2330210A1 (fr) | 1999-12-23 |
Family
ID=27517463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002330210A Abandoned CA2330210A1 (fr) | 1998-06-13 | 1999-06-10 | Activite de proteasomes |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1088100A2 (fr) |
| JP (1) | JP2002518020A (fr) |
| AU (1) | AU4281199A (fr) |
| CA (1) | CA2330210A1 (fr) |
| WO (1) | WO1999066065A2 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9914648A (pt) * | 1998-10-20 | 2001-11-27 | Millennium Pharm Inc | Processo para monitorar ação medicamentosa deinibidor de proteasoma |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5587300A (en) * | 1994-04-26 | 1996-12-24 | Wisconsin Ulumni Research Foundation | Method to increase regulatory molecule production |
| US5693483A (en) * | 1996-01-05 | 1997-12-02 | Icos Corporation | Cytoplasmic modulators of integrin binding/signalling |
| US5932425A (en) * | 1997-02-18 | 1999-08-03 | Signal Pharmaceuticals, Inc. | Compositions and methods for modulating cellular NF-κB activation |
| EP0943624A1 (fr) * | 1998-03-12 | 1999-09-22 | Universiteit Utrecht | Inhibiteurs peptidiques de la rétrorégulation du récepteur de l'hormone de croissance |
-
1999
- 1999-06-10 JP JP2000554874A patent/JP2002518020A/ja active Pending
- 1999-06-10 WO PCT/GB1999/001840 patent/WO1999066065A2/fr not_active Application Discontinuation
- 1999-06-10 EP EP99957075A patent/EP1088100A2/fr not_active Withdrawn
- 1999-06-10 CA CA002330210A patent/CA2330210A1/fr not_active Abandoned
- 1999-06-10 AU AU42811/99A patent/AU4281199A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999066065A2 (fr) | 1999-12-23 |
| WO1999066065A3 (fr) | 2000-04-20 |
| AU4281199A (en) | 2000-01-05 |
| EP1088100A2 (fr) | 2001-04-04 |
| JP2002518020A (ja) | 2002-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cesaro et al. | Inhibition of PKR by Viruses | |
| Kim et al. | Emerging roles of desumoylating enzymes | |
| Hara et al. | Influenza virus RNA polymerase PA subunit is a novel serine protease with Ser624 at the active site | |
| Kawai et al. | Toll‐like receptor and RIG‐1‐like receptor signaling | |
| Mermoud et al. | Ser/Thr-specific protein phosphatases are required for both catalytic steps of pre-mRNA splicing | |
| Raines | Ribonuclease a | |
| Reyes-Turcu et al. | Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes | |
| Jentsch | Ubiquitin-dependent protein degradation: a cellular perspective | |
| Zong et al. | The functional deubiquitinating enzymes in control of innate antiviral immunity | |
| Barik et al. | Phosphorylation by cellular casein kinase II is essential for transcriptional activity of vesicular stomatitis virus phosphoprotein P. | |
| Gusho et al. | New advances in our understanding of the “unique” RNase L in host pathogen interaction and immune signaling | |
| Gale Jr et al. | Translational control of viral gene expression in eukaryotes | |
| Honig et al. | Crimean–Congo hemorrhagic fever virus genome L RNA segment and encoded protein | |
| Chen et al. | Degradation of p21cip1 in cells productively infected with human cytomegalovirus | |
| Cheng et al. | Identification of potential target genes for Adr1p through characterization of essential nucleotides in UAS1 | |
| Yi et al. | Histone tail cleavage as a novel epigenetic regulatory mechanism for gene expression | |
| O'Neill et al. | Inhibition of translation in cells infected with a poliovirus 2Apro mutant correlates with phosphorylation of the alpha subunit of eucaryotic initiation factor 2 | |
| Lindner | Deubiquitination in virus infection | |
| Azad et al. | Proteolytic clipping of histone tails: the emerging role of histone proteases in regulation of various biological processes | |
| Rubinstein et al. | Infection of HeLa cells with poliovirus results in modification of a complex that binds to the rRNA promoter | |
| Richter et al. | Function of the stromal processing peptidase in the chloroplast import pathway | |
| Barretto et al. | Deubiquitinating activity of the SARS-CoV papain-like protease | |
| Greer | Assembly of a tRNA splicing complex: evidence for concerted excision and joining steps in splicing in vitro | |
| CA2330210A1 (fr) | Activite de proteasomes | |
| Karasik et al. | The unusual role of ribonuclease L in innate immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |